Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
Background: Outcomes-based reimbursement (OBR) can reduce decision uncertainty and accelerate patient access to cell and gene therapies, however, OBR is rarely applied in practice in England. Oncology is the therapy area with the most cell and gene therapies in late-stage development, and the System...
Saved in:
Main Authors: | Jesper Jørgensen (Author), Panos Kefalas (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020) -
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017) -
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease
by: Jesper Jørgensen, et al.
Published: (2018) -
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching
by: Jesper Jørgensen, et al.
Published: (2019) -
The EBMT Handbook Hematopoietic Stem Cell Transplantation and Cellular Therapies /
Published: (2019)